|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
A total of 30 adults with chronic fatigue syndrome filled in the Cognitive Emotion Regulation Questionnaire, the COPE and the Hospital Anxiety and Depression Scale.
|
28810458 |
2019 |
|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
Problem-focused coping was measured by the three dimensions of active coping, planning, and using instrumental support from the Brief COPE scale, and depression was assessed by the Self-rating Depression Scale.
|
31841535 |
2019 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
A total of 30 adults with chronic fatigue syndrome filled in the Cognitive Emotion Regulation Questionnaire, the COPE and the Hospital Anxiety and Depression Scale.
|
28810458 |
2019 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
Problem-focused coping was measured by the three dimensions of active coping, planning, and using instrumental support from the Brief COPE scale, and depression was assessed by the Self-rating Depression Scale.
|
31841535 |
2019 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
A total of 30 adults with chronic fatigue syndrome filled in the Cognitive Emotion Regulation Questionnaire, the COPE and the Hospital Anxiety and Depression Scale.
|
28810458 |
2019 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Problem-focused coping was measured by the three dimensions of active coping, planning, and using instrumental support from the Brief COPE scale, and depression was assessed by the Self-rating Depression Scale.
|
31841535 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), and coping (Brief COPE) at baseline and 24 weeks.
|
29140772 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Questionnaires addressed patients' experience with cancer and included measures of coping (COPE and Emotional Approach Coping), social support (Interpersonal Support Evaluation List), and depressive symptoms (Center for Epidemiologic Studies Depression Scale).
|
29265835 |
2018 |
|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
We measured stress coping (an abbreviated version of the COPE Inventory: Brief COPE) and depression (the Japanese version of the Beck Depression Inventory-II: BDI-II).
|
28857394 |
2018 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
We measured stress coping (an abbreviated version of the COPE Inventory: Brief COPE) and depression (the Japanese version of the Beck Depression Inventory-II: BDI-II).
|
28857394 |
2018 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
We measured stress coping (an abbreviated version of the COPE Inventory: Brief COPE) and depression (the Japanese version of the Beck Depression Inventory-II: BDI-II).
|
28857394 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Questionnaires addressed patients' experience with cancer and included measures of coping (COPE and Emotional Approach Coping), social support (Interpersonal Support Evaluation List), and depressive symptoms (Center for Epidemiologic Studies Depression Scale).
|
29265835 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), and coping (Brief COPE) at baseline and 24 weeks.
|
29140772 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis.
|
28574777 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Study participants from a comprehensive cancer center were asked to complete a series of instruments that measured their perception of the patient's cognitive dysfunction (revised memory and behavior problems checklist, RMBC), their own personal resilience (Resilience Scale, RS), and their utilization of a broad range of coping responses (COPE inventory and Emotional-Approach Coping scale).
|
27921222 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We report the validation process of a 4-factor structure of the French version of the Brief COPE in a French sample of individuals facing a singular life event, such as cancer, including patients and their caregivers.
|
28077139 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis.
|
28574777 |
2017 |
|
Mental Depression
|
0.060 |
Biomarker
|
disease |
BEFREE |
Patients completed a set of questionnaires on working status and educational level, physical functioning (Frenchay Activities Index, FAI), mental functioning (Hospital Anxiety and Depression Scale, HADS), Coping Orientations to Problems Experienced, (COPE easy) and quality of life (Short-Form(SF)-36 and EQ(Euroqol)-5D).
|
27402347 |
2017 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis.
|
28574777 |
2017 |
|
Depressive disorder
|
0.060 |
Biomarker
|
disease |
BEFREE |
Patients completed a set of questionnaires on working status and educational level, physical functioning (Frenchay Activities Index, FAI), mental functioning (Hospital Anxiety and Depression Scale, HADS), Coping Orientations to Problems Experienced, (COPE easy) and quality of life (Short-Form(SF)-36 and EQ(Euroqol)-5D).
|
27402347 |
2017 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer.
|
27725249 |
2017 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis.
|
28574777 |
2017 |